Search Results
Oct 13, 2025, 08:00 ET Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration
of domestic ADC innovators into global supply chains. This achievement further strengthens Thousand Oaks Biologics' competitiveness in the international biopharmaceutical market. The company will use this accomplishment as a foundation to continue enhancing its ADC technology platforms—including
More news about: Thousand Oaks Biologics
Oct 13, 2025, 08:00 ET Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration
of domestic ADC innovators into global supply chains. This achievement further strengthens Thousand Oaks Biologics' competitiveness in the international biopharmaceutical market. The company will use this accomplishment as a foundation to continue enhancing its ADC technology platforms—including
More news about: Thousand Oaks Biologics
Oct 13, 2025, 07:30 ET ADC Therapeutics Announces $60 Million Private Placement
therapy. About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for
More news about: ADC Therapeutics SA
Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers.
More news about: AbbVie
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
FGFR3 inhibitor, in FGFR3-altered urothelial cancer. LY4170156 (investigational ADC targeting FRα): In a poster presentation, Lilly will share updated safety and efficacy results from the Phase 1a/1b
More news about: Eli Lilly and Company
Oct 13, 2025, 05:00 ET SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
Iza-bren is a potential first-in-class bispecific topoisomerase 1 inhibitor-based antibody-drug conjugate (ADC) that targets both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It is being developed by SystImmune's
More news about: SystImmune, Inc.
Oct 11, 2025, 08:45 ET C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
Drug Conjugate (RDC) field and reinforces its leadership in large-molecule oncology therapies (ADC/GNC/ARC). The company's flagship asset BL-B01D1 (a first-in-class EGFR×HER3 bispecific ADC) set a record-breaking global licensing deal of USD 8.4 billion, underscoring Biokin's innovation
More news about: C Ray Therapeutics
Oct 09, 2025, 17:31 ET Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight
validation of FRα as a predictive biomarker for ELAHERE (mirvetuximab soravtansine) marks a shift toward targeted, biomarker-driven therapies. As the only ADC evaluated in a pivotal PROC trial, mirvetuximab leverages FRα overexpression in ovarian tumors to deliver cytotoxic payloads selectively, offering a
More news about: DelveInsight Business Research, LLP
Oct 09, 2025, 08:22 ET Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
Concurrently, the company continues to push the boundaries of GI cancer treatment by developing next-generation therapies, such as the PD-L1-targeting ADC HLX43, now in clinical studies for advanced gastric/gastroesophageal junction adenocarcinoma and other tumors. Looking ahead,
More news about: Henlius
Oct 09, 2025, 07:00 ET Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma
ADCE-D01 is a first-in-class ADC targeting urokinase plasminogen activator receptor-associated protein (uPARAP) conjugated to the Topoisomerase I inhibitor payload P1021. uPARAP is a novel endocytic ADC target that is overexpressed in tumors of mesenchymal origin, such
More news about: Adcendo
Oct 09, 2025, 07:00 ET Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma
ADCE-D01 is a first-in-class ADC targeting urokinase plasminogen activator receptor-associated protein (uPARAP) conjugated to the Topoisomerase I inhibitor payload P1021. uPARAP is a novel endocytic ADC target that is overexpressed in tumors of mesenchymal origin, such
More news about: Adcendo
Oct 09, 2025, 06:00 ET Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
conjugate (ADC) discovery by predicting response mechanisms, informing ADC positioning, and reducing the need for large-scale cell line screens. This collaboration will apply Turbine's platform, which virtualizes biological experiments at scale, to not only improve the efficiency and speed of ADC discovery
More news about: Turbine
Oct 07, 2025, 08:00 ET TIE 2025: MOEA DoIT to Demonstrate AI Innovations with Eye-Catching Tech Waterfall Taking Center Stage
shown no significant toxic reactions. To date, no ADC drugs targeting NTSR1 exist worldwide. Should it reach the market, this will be the world's first NTSR1-targeted ADC drug, enabling Taiwan to capture global market share and strengthen its autonomous ADC development capabilities.
More news about: Taiwan Innotech Expo
Oct 07, 2025, 07:00 ET TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress
Series C financing. Additionally, updated results from the ongoing Phase 1 study of the Company's Claudin 6 (CLDN6) targeted antibody-drug conjugate (ADC) TORL-1-23 in patients with advanced cancer will be presented in poster sessions at the 2025 European Society of Medical Oncology Congress (ESMO 2025)
More news about: TORL Biotherapeutics LLC
Oct 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment
More news about: ADC Therapeutics SA
Oct 01, 2025, 06:00 ET Digital Experience Platform Market worth USD 26.5B by 2030, Driven by Personalization & AI Integration, Says Mordor Intelligence
management platforms. Application Delivery Controllers Market: The Application Delivery Controllers (ADC) Market is expected to reach USD 3.42 billion in 2025 and rise to USD 5.26 billion by 2030, expanding at a Compound Annual Growth Rate (CAGR) of 8.98%
More news about: Mordor Intelligence Private Limited
Sep 30, 2025, 17:31 ET HPV-Positive Oropharyngeal Cancer Market Poised for Strong Growth by 2034, Driven by Rising Incidence and Treatment Innovation | DelveInsight
immunotherapy combinations are also gaining traction. The Versamune HPV doublet (Versamune HPV + KEYTRUDA) and the triplet regimen (Versamune HPV + PDS01ADC + Bintrafusp alfa) have demonstrated promising efficacy. They are poised to transform the treatment paradigm for HPV16+ head and neck squamous cell carcinoma
More news about: DelveInsight Business Research, LLP
Sep 30, 2025, 08:00 ET AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
development and chief scientific officer, AbbVie. "We look forward to next steps in the regulatory process for our latest Antibody-Drug Conjugate (ADC), our first ADC in blood cancer, and how it may advance treatment for those living with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)."
More news about: AbbVie
Sep 29, 2025, 17:31 ET DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
than acyclovir. Merck's Ifinatamab deruxtecan (MK-2400) is an investigational antibody-drug conjugate (ADC) composed of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. Co-developed with Daiichi Sankyo, it is in
More news about: DelveInsight Business Research, LLP
Sep 29, 2025, 09:00 ET AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
have received one to three prior systemic treatment regimens.1 ELAHERE is the first-and-only approved FRα-directed antibody drug conjugate (ADC) medicine. "Scientific progress in treating ovarian cancer and other serious diseases requires a collaborative approach among
More news about: AbbVie
Sep 26, 2025, 22:45 ET The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
and breakthrough strategies in the overseas expansion of China's ADC drugs. First, Dr. Stuart mentioned that the wave of overseas expansion of China's ADC drugs is accelerating, and China has become an indispensable force in the global ADC industry landscape. Product safety, quality stability, and compliance
More news about: WuXi XDC
Sep 25, 2025, 03:30 ET Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license
More news about: Synaffix
Sep 24, 2025, 07:00 ET SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
antibody drug conjugate (ADC) pipeline, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. Iza-bren, a potentially first-in-class EGFRxHER3 bispecific ADC, is jointly developed by
More news about: SystImmune, Inc.
Sep 23, 2025, 08:00 ET TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer
with Boehringer Ingelheim. The partnership will leverage TegMine's proprietary 2-Factor Antibody System to develop more selective and better-tolerated ADC therapeutics. The collaboration is centered on an initial program targeting a clinically validated antigen, with the potential to expand to two
More news about: TegMine Therapeutics
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 1 ADC project approved for marketing,1 ADC project in NDA stage and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.